Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Register

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Login
EN FR
Healthcare professional and patient

PrSymbicort® budesonide/formoterol fumarate dihydrate

Welcome to
SYMBICORT

A website for Canadian healthcare professionals
Download CTS Summary Booklet Download SYMBICORT TURBUHALER Leave Behind
SYMBICORT TURBUHALER: The #1 dispensed ICS/LABA1

SYMBICORT TURBUHALER:

The #1 dispensed
ICS/LABA1

The #1
dispensed
ICS/LABA1

About SYMBICORT® TURBUHALER®

In Canada, SYMBICORT TURBUHALER is indicated for2

The treatment of asthma in patients 12 years and older with reversible obstructive airways disease.

In Canada, SYMBICORT 200 TURBUHALER and SYMBICORT FORTE TURBUHALER are indicated for2

The maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate.

Learn more about SYMBICORT TURBUHALER and access resources
designed to help you support your patients below.

COPD: chronic obstructive pulmonary disease; CTS: Canadian Thoracic Society; ICS: inhaled corticosteroid; LABA: long-acting beta2-adrenergic agonist.

 

References:

  • Data on file. AstraZeneca Canada Inc. April 15, 2024.
  • Symbicort® Turbuhaler® Product Monograph. AstraZeneca Canada Inc. February 8, 2021.
Back to Top